biz is booming

3 Houston companies make Deloitte's fastest-growing tech list

Three Houston tech companies are seeing big business growth, according to Deloitte's report. Graphic via Deloitte

Three Houston companies have earned spots on this year's edition of the North American Technology Fast 500.

The three Houston honorees are:

  • Enercross, a provider of logistics software for the energy sector. It appears at No. 31 on the Fast 500 list, with revenue growth of 6,230 percent from 2017 to 2020.
  • Onit, which offers workflow and AI technology for legal, compliance, sales, IT, HR, and finance departments. It lands at No. 304, with a 408 percent rise in revenue from 2017 to 2020. According to Crunchbase, Onit has reeled in $216.6 million in venture capital.
  • Graylog, a provider of log management software. It sits at No. 309, with revenue growth of 402 percent from 2017 to 2020. Graylog has collected $27.4 million in venture capital, according to Crunchbase. That includes an $18 million round announced this summer.

The North America Technology Fast 500, sponsored by professional services firm Deloitte, is an annual ranking of the fastest-growing tech, media, telecom, life sciences, and energy tech companies in North America.

"The Houston companies on this year's Fast 500 list are transforming the way our city does business by combining technological innovation with entrepreneurial spirit," Amy Chronis, Houston managing partner at Deloitte, says in a news release. "I'm inspired by the ways these organizations have succeeded amid unprecedented times, and I look forward to seeing their progress in 2022."

The top-ranked company is Irvine, California-based medical device company Axonics, whose revenue soared 87,037 percent from 2017 to 2020. The top-ranked Texas company is Austin-based Shipwell, where revenue climbed 32,670 percent from 2017 to 2020. Shipwell provides a shipment-tracking platform. Overall, 5 percent of the Fast 500 companies are based in Texas.

Both Enercross and Onit showed up on last year's Fast 500. Enercross ranked 37th in 2020, with revenue growth of 5,881 percent, and Onit ranked 190th, with revenue growth of 641 percent. Meanwhile, Graylog is a new entrant this year.

Two Houston companies fell off the Fast 500 this year:

  • Lexicon Pharmaceuticals, which ranked 328th last year with revenue growth of 306 percent.
  • Vendor Credentialing Services (symplr), a tech platform that simplifies vendor services, compliance, and more for health professionals. It appeared at No. 426 last year, notching revenue growth of 221 percent.

Not surprisingly, Silicon Valley accounted for one-fifth of the companies in this year's Fast 500, followed by the New York City metro area (12 percent) and New England (8 percent). Nearly three-fourths of the Fast 500 companies specialize in software, and 81 percent of the companies have received venture capital at some point.

"Each year, the Technology Fast 500 shines a light on leading innovators in technology, and this year is no exception," says Paul Silverglate, leader of the U.S. technology sector at Deloitte. "In the face of innumerable challenges resulting from the pandemic, the best and brightest were able to pivot, reinvent and transform and grow."

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted